Publications by authors named "D Poddubnyy"
Objectives: In this post-hoc analysis of ESTHER trial, we aimed to investigate the longitudinal relationship between inflammation on MRI and the achievement of inactive disease/low disease activity in patients with axial spondyloarthritis (axSpA) treated with long-term tumor necrosis factor (TNF) inhibitor etanercept.
Methods: Of the 76 patients with active axSpA in the ESTHER trial, we included all patients treated with etanercept for at least 6 months for main analysis. All clinical and MRI data from 4.
Objectives: The objective of this study is to investigate lipopolysaccharid-binding protein (LBP), zonulin and calprotectin as markers of bacterial translocation, disturbed gut barrier and intestinal inflammation in patients with radiographic axial spondyloarthritis (r-axSpA) during tumour necrosis factor inhibitor (TNFi) therapy and to analyze the association between disease activity, response to treatment and biomarker levels.
Methods: Patients with active r-axSpA of the German Spondyloarthritis Inception Cohort starting TNFi were compared with controls with chronic back pain. Serum levels of LBP, zonulin and calprotectin were measured at baseline and after 1 year of TNFi therapy.
Purpose: To examine whether incorporating anatomy-centred deep learning can improve generalisability and enable prediction of disease progression.
Methods: This retrospective multicentre study included conventional pelvic radiographs of four different patient cohorts focusing on axial spondyloarthritis collected at university and community hospitals. The first cohort, which consisted of 1483 radiographs, was split into training (n=1261) and validation (n=222) sets.
Background: To assess gender differences in a large sample of patients included in the International Map of Axial Spondyloarthritis (IMAS) study from around the globe.
Method: IMAS is a cross-sectional online survey (2017-2022) of 5557 unselected axSpA patients from 27 countries. The current analysis assessed differences between males and females for: sociodemographic, health behaviors, disease characteristics, patient-reported outcomes, mental comorbidities, and treatments.
Article Synopsis
- The study aimed to evaluate the occurrence of extra-musculoskeletal manifestations (EMMs) in patients with psoriatic arthritis (PsA) or axial spondyloarthritis (axSpA) treated with a specific medication, upadacitinib (UPA15).
- Data from five clinical trials were analyzed to compare adverse events like uveitis and inflammatory bowel disease (IBD) among patients receiving either UPA15, a placebo, or adalimumab (ADA).
- Results showed that most patients did not have a history of EMMs, and the occurrence of uveitis and IBD was generally low, particularly in those treated with UPA15 compared to the placebo.